SPL Medical announces long-term distribution agreement partnership for its novel contrast agent Ferrotran® (Ferumoxtran) for the Korean market

SPL Medical announces long-term distribution agreement partnership for its novel contrast agent Ferrotran® (Ferumoxtran) for the Korean market

SPL Medical announced today that it has entered into an agreement for the distribution of its novel contrast agent Ferrotran® for the Korean market with Encormac Corp.

No Comments

Sorry, the comment form is closed at this time.